Clinical Trial News and Research

RSS

Healthy snacks can aid weight-loss efforts

Women dieters who grab a snack between breakfast and lunch lose less weight compared to those who abstain from a mid-morning snack, according to a study led by researchers at Fred Hutchinson Cancer Research Center.

28 Nov 2011

Bayer, Regeneron commence EYLEA Phase 3 clinical trial for wet AMD in China

Regeneron Pharmaceuticals, Inc. and Bayer HealthCare today announced that they have initiated a Phase 3 clinical trial evaluating the efficacy and safety of EYLEA (aflibercept) Injection in the neovascular form of age-related macular degeneration (wet AMD) in China.

28 Nov 2011

Inspiration initiates second OBI-1 phase III clinical trial in congenital hemophilia A with inhibitors

Ipsen today announced that its partner Inspiration Biopharmaceuticals, Inc. has initiated the treatment of the first patient in the second of two pivotal studies from the OBI-1's Accur8 clinical trial program.

28 Nov 2011

Moleac launches NurAiD II in France and Belgium

Biopharmaceutical Company Moleac has announced the launch in France and Belgium of NurAiD II. NurAiD II is a natural health supplement engineered to stimulate neuroplasticity and recovery.

25 Nov 2011

Immunicum receives Swedish approval to commence first clinical trial of patented cancer vaccine

Immunicum, which is developing cancer vaccines, has received approval from the Swedish Medical Products Agency to start its first clinical trial. The study will be conducted on kidney cancer patients at the University Hospital in Uppsala. At the same time, the company secures substantial financing to complete the clinical trial.

25 Nov 2011

NIH-led study advances HIV vaccine research

HIV is coated in sugars that usually hide the virus from the immune system. Newly published research reveals how one broadly neutralizing HIV antibody actually uses part of the sugary cloak to help bind to the virus. The antibody binding site, called the V1/V2 region, represents a suitable HIV vaccine target, according to the scientists who conducted the study. In addition, their research reveals the detailed structure of the V1/V2 region, the last part of the virus surface to be visualized at the atomic level.

24 Nov 2011

Combination of radiation treatment and LY2109761 can prevent glioblastoma

Glioblastoma is regarded as the most malignant form of brain tumor. In many cases, neurosurgeons are not able to remove such tumors completely because of the risk of destroying too much brain tissue in the process. Moreover, it is often impossible to identify all the fine extensions by which the tumor spreads into surrounding healthy tissue. To at least slow down the growth of tumor cells that have remained in the head, almost all glioblastoma patients are treated by radiotherapy after surgery.

24 Nov 2011

New Techna Institute at UHN signs first agreement with INO

The new Techna Institute at University Health Network (UHN) has signed its first agreement with INO of Quebec City and Hamilton.

24 Nov 2011

Study evaluates safety and effectiveness of Diamondback device for heart attacks

Drilling through concrete to create an opening may sound more like construction than medicine, but the approach is similar to what researchers at Orlando Regional Medical Center (ORMC) are doing in a clinical trial to evaluate a device that breaks through hardened coronary arteries, in an effort to prevent heart attacks and relieve chest pain.

23 Nov 2011

Treatment of Type 1 diabetes patients with DiaPep277- may have several medical benefits

The clinical trial was random, regulated, double-blinded and broad-based. The drug was tested on 457 patients, aged 16-45, who had been diagnosed with Type 1 diabetes a short time before joining the trial. The trial took place in around 40 medical centers in Europe, Israel and South Africa. The patients in the trial were randomly assigned to one of two groups: One received the trial drug (DiaPep277-) through a subcutaneous injection once every three months, for a period of two years, while the control group was given a placebo in the same way.

23 Nov 2011

Arginine may reactivate T-cells in patients with glioblastoma

In many cases, tumors suppress a patient's immune system in a way that keeps the cancer safe from immune system attack. This is particularly true for patients with glioblastoma, a primary brain tumor that carries a prognosis of only 12-15 months survival after diagnosis.

22 Nov 2011

Cognitive-behavioral therapy safe and effective for juvenile fibromyalgia

A recent trial shows cognitive-behavioral therapy (CBT) reduces functional disability and depressive symptoms in adolescents with juvenile fibromyalgia. The psychological intervention was found to be safe and effective, and proved to be superior to disease management education.

22 Nov 2011

U-M ranks sixth among all medical schools in NIH funding

Research at the University of Michigan Medical School brought hundreds of millions of dollars into the state of Michigan in the last year - and could have a total economic impact of nearly $1.2 billion, new data show.

22 Nov 2011

FDA clears TSC's OncoTrac medical imaging software

Translational Sciences Corporation (TSC) announced today that it has received FDA 510(k) clearance for commercialization of its OncoTrac medical imaging software.

22 Nov 2011

Scientists design math model that could guide future prostate cancer treatments

Scientists have designed a first draft of a mathematical model that someday could guide treatment decisions for advanced prostate cancer, in part by helping doctors predict how individual patients will respond to therapy based on the biology of their tumors.

22 Nov 2011

Breast cancer drug Avastin loses FDA support

According to a Food and Drug Administration (FDA) announcement last Friday, the cancer drug Avastin should not be used to treat breast cancer that has spread to other organs because it doesn't help patients enough to justify its risky side effects.

21 Nov 2011

Covidien to acquire BÂRRX Medical

Covidien, a leading global provider of healthcare products and a world leader in advanced energy-based devices, today announced a definitive agreement to acquire BÂRRX Medical, Inc. BÂRRX is the leader in treatment of Barrett's esophagus syndrome using bipolar radiofrequency (RF) ablation devices.

21 Nov 2011

Nature Medicine publishes dexpramipexole Phase 2 ALS study results

Knopp Biosciences LLC today announced the publication in Nature Medicine of comprehensive results from the Phase 2 study of dexpramipexole, a small-molecule modulator of mitochondrial bioenergetics, in people with amyotrophic lateral sclerosis.

21 Nov 2011

2011 National Report Card on Lung Cancer notes significant change in grade for early detection

Today, Lung Cancer Alliance (LCA), the leading national support and advocacy voice for those at risk for or living with lung cancer, issued its annual 2011 National Report Card on Lung Cancer, an overall assessment of the nation's response to the continuing high mortality of lung cancer, the leading cause of cancer death.

21 Nov 2011

UTHealth and Memorial Hermann HVI first in Houston to implant FDA approved artificial heart valve

Cardiologists and cardiovascular surgeons at The University of Texas Health Science Center at Houston and Memorial Hermann Heart & Vascular Institute are the first in Houston to implant the artificial heart valve recently approved by the Food and Drug Administration, as well as a newer, smaller version that is part of a clinical trial.

21 Nov 2011